Robert A Fridell
Overview
Explore the profile of Robert A Fridell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marquis K, Everett J, Cantu A, McFarland A, Sherrill-Mix S, Krystal M, et al.
AIDS Res Hum Retroviruses
. 2023 May;
40(2):114-126.
PMID: 37125442
Decades of effort have yielded highly effective antiviral agents to treat HIV, but viral strains have evolved resistance to each inhibitor type, focusing attention on the importance of developing new...
2.
Wang C, Huang H, Mallon K, Valera L, Parcella K, Cockett M, et al.
Antimicrob Agents Chemother
. 2023 Apr;
67(5):e0169422.
PMID: 37039636
GSK878 is a newly described HIV-1 inhibitor that binds to the mature capsid (CA) hexamer in a pocket originally identified as the binding site of the well-studied CA inhibitor PF-74....
3.
Sun J, OBoyle 2nd D, Fridell R, Langley D, Wang C, Roberts S, et al.
Nature
. 2015 Nov;
527(7577):245-8.
PMID: 26536115
It is estimated that more than 170 million people are infected with hepatitis C virus (HCV) worldwide. Clinical trials have demonstrated that, for the first time in human history, the...
4.
Wang C, Jia L, OBoyle 2nd D, Sun J, Rigat K, Valera L, et al.
Antimicrob Agents Chemother
. 2014 Jun;
58(9):5155-63.
PMID: 24936600
A comparison of the daclatasvir (DCV [BMS-790052]) resistance barrier on authentic or hybrid replicons containing NS5A from hepatitis C virus (HCV) genotypes 1 to 6 (GT-1 to -6) was completed...
5.
Belema M, Lopez O, Bender J, Romine J, Laurent D, Langley D, et al.
J Med Chem
. 2014 Mar;
57(5):1643-72.
PMID: 24621191
Lead inhibitors that target the function of the hepatitis C virus (HCV) nonstructural 5A (NS5A) protein have been identified by phenotypic screening campaigns using HCV subgenomic replicons. The demonstration of...
6.
Belema M, Nguyen V, Bachand C, Deon D, Goodrich J, James C, et al.
J Med Chem
. 2014 Feb;
57(5):2013-32.
PMID: 24521299
The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains...
7.
Belema M, Nguyen V, Romine J, Laurent D, Lopez O, Goodrich J, et al.
J Med Chem
. 2014 Jan;
57(5):1995-2012.
PMID: 24437689
A medicinal chemistry campaign that was conducted to address a potential genotoxic liability associated with an aniline-derived scaffold in a series of HCV NS5A inhibitors with dual GT-1a/-1b inhibitory activity...
8.
OBoyle Ii D, Sun J, Nower P, Lemm J, Fridell R, Wang C, et al.
Virology
. 2013 Jul;
444(1-2):343-54.
PMID: 23896639
The hepatitis C virus NS5A protein is an established and clinically validated target for antiviral intervention by small molecules. Characterizations are presented of compounds identified as potent inhibitors of HCV...
9.
Belema M, Nguyen V, Laurent D, Lopez O, Qiu Y, Good A, et al.
Bioorg Med Chem Lett
. 2013 Jun;
23(15):4428-35.
PMID: 23803586
The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a...
10.
Wang C, Sun J, OBoyle 2nd D, Nower P, Valera L, Roberts S, et al.
Antimicrob Agents Chemother
. 2013 Feb;
57(5):2054-65.
PMID: 23403428
Daclatasvir (DCV; BMS-790052) is a hepatitis C virus (HCV) NS5A replication complex inhibitor (RCI) with picomolar to low nanomolar potency and broad genotypic coverage in vitro. Viral RNA declines have...